Why the study?
This study aimed to identify and quantify the importance of risk factors for gastrointestinal bleeding in patients with CV disease.
What are the independent risk factors and their population attributable fractions for gastrointestinal bleeding in patients with cardiovascular disease?
What are the independent risk factors and their population attributable fractions for gastrointestinal bleeding in patients with cardiovascular disease?
In patients with cardiovascular disease, known potentially modifiable risk factors—including antithrombotic therapy within 6 months—account for only about one-third (37.3%) of the population attributable risk for gastrointestinal bleeding, and only about one-quarter (25.6%) in patients aged 71 and older.
Highlights modifiable risk factors for GI bleeding in CV disease; leaves open whether targeted interventions improve outcomes.
AIMS: This study aimed to identify and quantify the importance of risk factors for gastrointestinal (GI) bleeding in patients with CV disease. METHODS: We conducted a case-control study in 9 countries in Asia, America, Europe, and Australia. Cases were patients with CV disease with GI bleeding. Controls were patients with CV without a history of GI bleeding. All participants completed a baseline standardized assessment. We calculated adjusted odds ratios (ORs) and average population attributable fractions (aPAFs) with 95% confidence intervals (CIs). RESULTS: Between September 2015 and December 2022, we enrolled 2,519 cases and 2,202 controls. Independent risk factors for GI bleeding were age (age 71+: OR 4.16, 95% CI 3.48-4.97; age 61-70: OR 1.69, 95% CI 1.39-2.04; age ≤60 as reference), underweight (OR 3.38, 95% CI 2.24-5.10; aPAF 1.6%, 95% CI 1.0-2.0%), current smoker (OR 1.31; 95% CI 1.09-1.58; aPAF 1.5%, 95% CI 0.6-2.5); chronic kidney disease (OR 1.86, 95% CI 1.62-2.14; aPAF 8.8%, 95% CI 7.0-9.6%), prior stroke (OR 1.56, 95% CI 1.30-1.88, aPAF 2.6%, 95% CI 1.2-4.0%), glucocorticoids (OR 1.71, 95% CI 1.34-2.16, aPAF 1.8%, 95% CI 1.3-2.9%), NSAIDs or COX-2 inhibitors (OR 1.82, 95% CI 1.45-2.29; aPAF 2.2%, 95% CI 1.3-3.0%), liver disease (OR 3.68, 95% CI 2.77-4.89; aPAF 3.5%, 95% CI 2.8-4.2%), peptic ulcer disease (OR 3.38, 95% CI 2.66-4.31; aPAF 4.8%, 95% CI 3.8-5.7%), diverticular disease (OR 1.81, 95% CI 1.46-2.24; aPAF 2.8%, 1.9-3.6%) and antithrombotic therapy within 6 months (aPAF 7.6%, 95% CI 4.3-12.8%). Overall aPAF adjusted for age, sex and region was 37.3% (95% CI 33.0-42.2%). CONCLUSION: Potentially modifiable risk factors are associated with only about one third of the aPAF for GI bleeding.
No takes yet. Share an insight, caveat, or question.
Bosch et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: